After Sezzle (SEZL) rallied from $200 to over $400, the stock lost 13.87% on Tuesday. The stock drop could continue, depending on how many investors sell to lock in their profits.
Sezzle has strong long-term prospects. It has two funnels to drive its subscriber growth.
Direct-to-consumer advertising is a new area for this buy now, pay later firm. The integrated merchant acquisition channel is the second source of attracting new customers.
Mosaic (MOS) will likely test and bounce back from the $25.00 support price. In Q3, the firm reported that three hurricanes hurt its Florida phosphate production. Weak selling prices hurt its revenue. Mosaic earned $122 million in profit but revenue fell by 21% Y/Y to $2.8 billion.
Traders may take advantage of the implied volatility in MOS stock through its options.
Amgen (AMGN) peaked at $325 – $340. Cantor posted a warning about the company’s obesity drug candidate, MariTide (AMG-133). The therapy may lead to bone mineral density loss in the subject. The warning is unusually timed. Amgen posted the Phase 1 trial data back in February.
Investors should watch for AMGN stock to hold its trading range above $300. If it bounces back, this stock is an attractive biotechnology holding for long-term investors.
